|
|
|
| Research progress of mesenchymal stem cells in the treatment of ankylosing spondylitis |
| LIU Donghan1 TAN Longwang2 ZHU Yu3 |
1.The First Clinical Medical College, Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712000, China;
2.Department of Spinal Orthopedics, Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712000, China;
3.Institute of Edcation, Ningxia University, Ningxia Hui Autonomous Region, Yinchuan 750021, China |
|
|
|
Abstract Ankylosing spondylitis is an autoimmune disease with a high clinical incidence. It is characterized by abnormal ossification and rigidity of the spine and sacroiliac joints, and with the further development of the disease, the patient’s quality of life is dramatically reduced. At present, the treatment of this disease is still a difficult problem in clinic. Considering the limitations of existing therapies (nonsteroidal anti-inflammatory drugs, glucocorticoids, antirheumatics, and biologic drugs), it is necessary to seek a treatment pathway with fewer side effects and higher potential. With the development of stem cell theory and technology, mesenchymal stem cells may be a new way to treat ankylosing spondylitis. This article reviews the basic and clinical research of mesenchymal stem cells in the treatment of ankylosing spondylitis in recent years, in order to provide new ideas for future research and application.
|
|
|
|
|
|
[1] Poddubnyy D. Classification vs diagnostic criteria：the challenge of diagnosing axial spondyloarthritis [J]. Rheumatology （Oxford），2020，59（Suppl4）：v6-v17.
[2] Navarro-Compán V，Sepriano A，El-Zorkany B，et al. Axial spondyloarthritis [J]. Ann Rheum Dis，2021，80（12）：1511- 1521.
[3] 刘鹄，任明亮，王潇娉，等.强直性脊柱炎患者骨髓间充质干细胞的生物学及免疫学特性[J].中国脊柱脊髓杂志，2012，22（6）：559-566.
[4] Kuca-Warnawin E，Janicka I，Bonek K，et al. Modulatory Impact of Adipose-Derived Mesenchymal Stem Cells of Ankylosing Spondylitis Patients on T Helper Cell Differentiation [J]. Cells，2021，10（2）：280.
[5] Kuca-Warnawin E，Plebańczyk M，Bonek K，et al. Direct anti-proliferative effect of adipose-derived mesenchymal stem cells of ankylosing spondylitis patients on allogenic CD4+ cells [J]. Reumatologia，2021，59（1）：12-22.
[6] Friedenstein AJ，Petrakova KV，Kurolesova AI，et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues [J]. Transplantation，1968，6（2）：230-247.
[7] Zhang Y，Pan Y，Liu Y，et al. Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulate regenerative wound healing via transforming growth factor-β receptor inhibition [J]. Stem Cell Res Ther，2021，12（1）：434.
[8] Purwaningrum M，Jamilah NS，Purbantoro SD，et al. Comparative characteristic study from bone marrow-derived mesenchymal stem cells [J]. J Vet Sci，2021，22（6）：e74.
[9] Chen HH，Chen YC，Yu SN，et al. Infrapatellar fat pad-derived mesenchymal stromal cell product for treatment of knee osteoarthritis：a first-in-human study with evaluation of the potency marker [J]. Cytotherapy，2022，24（1）：72-85.
[10] Bulati M，Miceli V，Gallo A，et al. The Immunomodulatory Properties of the Human Amnion-Derived Mesenchymal Stromal/Stem Cells Are Induced by INF-γ Produced by Activated Lymphomonocytes and Are Mediated by Cell-To-Cell Contact and Soluble Factors [J]. Front Immunol，2020，11：54.
[11] Kim YJ，Ahn HJ，Lee SH，et al. Effects of conditioned media from human umbilical cord blood-derived mesenchymal stem cells in the skin immune response [J]. Biomed Pharmacother，2020，131：110789.
[12] Merimi M，Buyl K，Daassi D，et al. Transcriptional Profile of Cytokines，Regulatory Mediators and TLR in Mesenchymal Stromal Cells after Inflammatory Signaling and Cell-Passaging [J]. Int J Mol Sci，2021，22（14）：7309.
[13] Sun J，Xing F，Zou M，et al. Comparison of chondrogenesis-related biological behaviors between human urine-derived stem cells and human bone marrow mesenchymal stem cells from the same individual [J]. Stem Cell Res Ther，2021，12（1）：366.
[14] Yorifuji H，Arase N，Kohyama M，et al. Transport of cellular misfolded proteins to the cell surface by HLA-B27 free heavy chain [J]. Biochem Biophys Res Commun，2019，511（4）：862-868.
[15] Londono J，Santos AM，Rueda JC，et al. Association of ERAP2 polymorphisms in Colombian HLA-B27+ or HLA- B15+ patients with SpA and its relationship with clinical presentation：axial or peripheral predominance [J]. RMD Open，2020，6（2）：e001250.
[16] Jah N，Jobart-Malfait A，Ermoza K，et al. HLA-B27 Subtypes Predisposing to Ankylosing Spondylitis Accumulate in an EndoplASmic Reticulum-Derived Compartment Apart From the Peptide-Loading Complex [J]. Arthritis Rheumatol，2020，72（9）：1534-1546.
[17] Wilbrink R，Spoorenberg A，Arends S，et al. CD27（-）CD38（low）CD21（low） B-Cells Are Increased in Axial Spondyloarthritis [J]. Front Immunol，2021，12：686273.
[18] Liu D，Liu B，Lin C，et al. Imbalance of Peripheral Lymphocyte Subsets in Patients With Ankylosing Spondylitis： A Meta-Analysis [J]. Front Immunol，2021，12：696973.
[19] Chen PM，Liu KJ，Hsu PJ，et al. Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2 [J]. J Leukoc Biol，2014，96（2）：295-303.
[20] Karussis D，Karageorgiou C，Vaknin-Dembinsky A，et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis [J]. Arch Neurol，2010，67（10）：1187-1194.
[21] Zhang Z，Huang S，Wu S，et al. Clearance of apoptotic cells by mesenchymal stem cells contributes to immunosuppression via PGE2 [J]. EBioMedicine，2019，45：341-350.
[22] Lee HK，Kim EY，Kim HS，et al. Effect of Human Mesenchymal Stem Cells on Xenogeneic T and B Cells Isolated fromLupus-Prone MRL.FAS （lpr） Mice [J]. Stem Cells Int，2020，2020：5617192.
[23] Lee HK，Kim HS，Pyo M，et al. Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Fas （lpr） mice [J]. Theranostics，2020，10（22）：10186-10199.
[24] Zhong L，Wang W，Song H. Complex role of IL-23R polymorphisms on ankylosing spondylitis：a meta-analysis [J]. Expert Rev Clin Immunol，2018，14（7）：635-643.
[25] Lee YH，Song GG. ASsociations between interleukin-23R polymorphisms and ankylosing spondylitis susceptibility：an updated meta-analysis [J]. Z Rheumatol，2019，78（3）：272-280.
[26] Yang Y，Shen ZY，Wu B，et al. Mesenchymal stem cells improve the outcomes of liver recipients via regulating CD4+ T helper cytokines in rats [J]. Hepatobiliary Pancreat Dis Int，2016，15（3）：257-265.
[27] Bi Y，Lin X，Liang H，et al. Human Adipose Tissue-Derived Mesenchymal Stem Cells in Parkinson's Disease： Inhibition of T Helper 17 Cell Differentiation and Regulation of Immune Balance Towards a Regulatory T Cell Phenotype [J]. Clin Interv Aging，2020，15：1383-1391.
[28] Hyv?覿rinen K，Holopainen M，Skirdenko V，et al. Mesenchymal Stromal Cells and Their Extracellular Vesicles Enhance the Anti-Inflammatory Phenotype of Regulatory Macrophages by Downregulating the Production of Interleukin （IL）-23 and IL-22 [J]. Front Immunol，2018，9：771.
[29] Ren C，Li M，Zheng Y，et al. Single-cell RNA-seq reveals altered NK cell subsets and reduced levels of cytotoxic molecules in patients with ankylosing spondylitis [J]. J Cell Mol Med，2022，26（4）：1071-1082.
[30] Wu D，Qin H，Wang Z，et al. Bone Mesenchymal Stem Cell- Derived sEV-Encapsulated Thermosensitive Hydrogels Accelerate Osteogenesis and Angiogenesis by Release of Exosomal miR-21[J]. Front Bioeng Biotechnol，2021，9：829136.
[31] Zheng Z，Guo Z，Zhong F，et al. A dual crosslinked hydrogel-mediated integrated peptides and BMSC therapy for myocardial regeneration [J]. J Control Release，2022，347：127-142.
[32] Abomaray F，Wagner AK，Chrobok M，et al. The Effect of Mesenchymal Stromal Cells Derived From Endometriotic Lesions on Natural Killer Cell Function [J]. Front Cell Dev Biol，2021，9：612714.
[33] 王亚莉，齐江彤，崔玉华，等.人脐带间充质干细胞移植治疗强直性脊柱炎[J].免疫学杂志，2015，31（1）：90-92.
[34] 苏鸿君，邓雯，冯佩.脐带间充质干细胞移植治疗强直性脊柱炎患者的效果分析[J].临床医学工程，2020，27（3）：295-296.
[35] 李晓昊，张军，曲海洪.经筋理论指导下微创针刀镜定植间充质干细胞治疗强直性脊柱炎髋关节病变的研究[J].现代中西医结合杂志，2019，28（19）：2063-2066.
[36] 孙素和，王鹏，苏春燕，等.强直性脊柱炎患者骨髓间充质干细胞调控巨噬细胞的功能异常[J].中国组织工程研究，2016，20（1）：13-19.
[37] 曲海洪，李晓昊，张军.不同剂量脐带间充质干细胞在针刀镜下定植治疗强直性脊柱炎患者病变髋关节的临床观察[J].国际感染病学（电子版），2019，8（2）：67-69.
[38] Wang P，Li Y，Huang L，et al. Effects and safety of allogenic mesenchymal stem cell intravenous infusion in activeankylosing spondylitis patients who failed NSAIDs：a 20-week clinical trial [J]. Cell Transplant，2014，23（10）：1293- 1303.
[39] 宋庆林.间充质干细胞治疗强直性脊柱炎36例临床分析[J].中国医学装备，2014，11（B08）：183-184.
[40] 彭肖，张艳，徐凤金，等.间充质干细胞治疗强直性脊柱炎的临床疗效[J].河北医学，2017，23（11）：1864-1867. |
|
|
|
